Immunic (IMUX) shares rose on Tuesday after Guggenheim launched its coverage with a Buy recommendation and a $7 target, citing the potential of its lead asset, vidofludimus calcium, designed to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results